• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilar Articles for the Week of August 1


Here are the top 5 biosimilar articles for the week of August 1, 2022.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of August 1, 2022.

Number 5: Results from a phase 3 trial suggested similar efficacy and safety of a denosumab biosimilar candidate Arylia (AryoGen Pharmed) to the reference product (Prolia) in postmenopausal osteoporosis.

Number 4: Biocon’s revenues for the quarter were up by 23% from last year, thanks to the success the company has had with biosimilars, of which revenues increased by 29%, and generic drugs, which had an increased revenue of 19%.

Number 3: Sandoz’ applications for its Tysabri biosimilar (natalizumab) and its high-concentration version of its Humira biosimilar (adalimumab) were accepted for review by the FDA and the European Medicines Agency.

Number 2: Prestige Biopharma and Intas Pharmaceuticals joined forces to partner on a bevacizumab biosimilar for multiple countries, and Hikma Pharmaceuticals makes a deal with Celltrion Healthcare for the commercialization of an adalimumab biosimilar.

Number 1: Generic drug manufacturer Teva Pharmaceuticals would pay $4.25 billion to settle more than 2500 lawsuits with states, local governments, and tribes over its role in the opioid epidemic under a settlement announced late Tuesday.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Ha Kung Wong, JD.
Here are the top 5 biosimilar articles for the week of April 15, 2024.
The Top 5 Biosimilars Articles for the Week of April 8, 2024.
Ha Kung Wong, JD.
Related Content
© 2024 MJH Life Sciences

All rights reserved.